Elemind, a Cambridge, MA-based AI-powered neurotech health company, raised $12M in Seed funding.
Backers included Village Global, LDV Partners, E14 Fund, Wharton’s Alumni Angel fund, Embark Ventures, as well as the founders of Skype, Nest, Opentable, Broadvision, Boston Scientific, Vital Proteins, and Fab Fit Fun.
The company intends to use the funds to further develop its first product ahead of its launch in the coming months.
Led by CEO Meredith Perry, Elemind is a neurotech health company that is pioneering “electric medicine,” which uses non-invasive, wearable neurotech to monitor and address issues in real-time with a breakthrough algorithm that reads and instantly responds to individual brainwaves. The company’s wearable neurotechnology reads individual brainwaves and guides them in real-time by responding with tailored stimulation.
The team includes:
- Dr. Ed Boyden, co-founder, has served as a neurotechnology professor at MIT for 17 years and pioneered the field of Optogenetics. He’s a Howard Hughes Medical Investigator and Stanford Neuroscience PhD. Boyden co-founded TI Solutions AG, SynLife, Cognito Therapeutics and Expansion Technologies, and won the Breakthrough Prize.
- Dr. David Wang, PhD in Artificial Intelligence from MIT, is co-founder and chief technology officer (CTO). Previously he was co-founder and CTO of the NuVu Innovation School.
- Dr. Ryan Neely, PhD Neuroscience from UC Berkeley where he studied brain-machine interfaces, is vice president, Science and Research. He held prior positions at Known Medicine and iota Biosciences, and studied and taught neuroscience at Harvard University.
- Dr. Nir Grossman, co-founder, is an 11-year neuroscience professor at Imperial College London and an MIT Research Fellow.
- Dr. Heather Read, co-founder, is a 21-year behavioral neuroscience and biomedical engineering professor at the University of Connecticut.
FinSMEs
07/02/2024